

Promore Pharma publishes prospectus

The prospectus that Promore Pharma AB (publ) ("Promore Pharma" or the "Company") has prepared in connection with the new share issue of approximately SEK 48.6 million with preferential rights for Promore Pharma's shareholders (the "Rights Issue") has today been approved by and registered with the Swedish Financial Supervisory Authority (the "SFSA").

Prospectus

The prospectus that Promore Pharma has prepared in connection with the upcoming Rights Issue has today been approved and registered with the SFSA. The prospectus, containing full terms and instructions, as well as a summarizing folder and application forms, can be obtained from Promore Pharma and Erik Penser Bank and will be kept available on Promore Pharma's website (www.promorepharma.com) and on Erik Penser Bank's website (www.penser.se). The prospectus will also be available on SFSA's website (www.fi.se). The summary folder will be sent by mail to Promore Pharma's direct and nominee registered shareholders in connection with the commencement of the subscription period of the Rights Issue.

Summary of the Rights Issue

- Shareholders in Promore Pharma receive one (1) subscription right per share held on the record date, June 1, 2021.
- Three (3) subscription rights entitle to subscription of two (2) new shares in Promore Pharma.
- The subscription price is SEK 2.00 per share.
- At full subscription, Promore Pharma will receive approximately SEK 48.6 million before issue costs.
- The Subscription period is June 3 - 17, 2021.
- Trading in subscription rights takes place during the period June 3 – 14, 2021.
- Trading in paid subscription shares (BTA) takes place as from June 3, 2021, until the Rights Issue has been registered with the Swedish Companies Registration Office.

Existing shareholders and external investors have signed subscription commitments and undertakings to subscribe via acceded subscription rights corresponding to an amount amounting to SEK 31.0 million. In addition, the Rights Issue is fully secured through underwritings.

Advisors

In connection with the Rights Issue, Promore has appointed Erik Penser Bank as financial advisor, and Setterwalls Advokatbyrå AB as legal advisor.

Important information

The information in this press release does not constitute an offer to acquire, subscribe or otherwise trade in shares or other securities issued by Promore Pharma AB. Invitation to interested parties to subscribe for shares in Promore Pharma AB is made through the prospectus that Promore Pharma AB has published.

The information in this press release may not be released, published, reproduced or distributed in or to the United States, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa or New Zealand or any other country or jurisdiction where such action is not permitted or where such action is subject to legal restrictions or would require further registration or other measures than what is required by Swedish law. Measures contrary to this instruction may constitute a breach of applicable securities legislation.

No shares have been registered, and will not be registered, in accordance with the United States Securities Act from 1933 ("Securities Act") and may not be offered, subscribed, sold or transferred, directly or indirectly, within the United States except after written approval from Promore Pharma AB and under an applicable exemption from the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or any other jurisdiction in the United States.

For additional information, please contact

Jonas Ekblom, CEO

Phone: [+46] 736 777 540

E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO

Phone: [+46] 708 565 245

E-mail: erik.magnusson@promorepharma.com

Promore Pharmas Certified Adviser is Erik Penser Bank

Tel: [+46] 8-463 83 00

E-mail: certifiedadviser@penser.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogenous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetic scars on the skin. Ropocamtide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

Link to prospectus

www.promorepharma.com/sv/section/investerare/prospekt/

Attachments

[Promore Pharma publishes prospectus](#)